Executives from Compass Pathways (NASDAQ:CMPS) discussed recent Phase 3 results for its COMP360 psilocybin program in treatment-resistant depression (TRD), highlighting statistically significant ...

2026年3月3日周二,Compass Pathways (NASDAQ:CMPS)在TD Cowen第46届年度医疗保健会议上发表演讲,公布了其治疗难治性抑郁症 (TRD)药物COMP360的III期临床试验令人鼓舞的结果。该公司在强调该药物疗效的同时,特别是25mg剂量的疗效,也讨论了监管审批和商业化策略方面的挑战。

伦敦和纽约 - Compass Pathways plc (NASDAQ:CMPS) 通过行权2025年1月13日发行的35,059,448份权证筹集了约2亿美元资金,该公司在新闻稿中表示。 这家生物技术公司正在向特定机构投资者发行15,160,619份美国存托股份,以及可购买至多19,898,829份美国存托股份的预付费权证以代替美国存托股份。 Compass ...

Across COMP005 and COMP006 to date, COMP360 is demonstrating a generally well-tolerated and safe profile, with treatment-emergent adverse events (TEAEs) being mild or moderate in severity, and the ...

Research will take place in the UK, including at the newly opened Centre for Mental Health Research and Innovation in London, developed in partnership with South London and Maudsley NHS Foundation ...

LONDON & NEW YORK--(BUSINESS WIRE)-- Compass Pathways plc (CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today reported its ...

COMPASS Pathways plc (NASDAQ:CMPS) is among the 7 Most Promising Psychedelic Stocks According to Hedge Funds. COMPASS Pathways plc (NASDAQ:CMPS) is given fourth position on our list of most promising ...

COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced that it has ...

The company's fresh look at psychedelic drugs is attracting lots of attention. Can the highly refined version of magic mushrooms that Compass Pathways is developing for depression give your portfolio ...

LONDON & NEW YORK--(BUSINESS WIRE)--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today ...

Compass Pathways has seen its shares slide in a big way this year. The drugmaker, however, has made significant progress on the clinical front in 2021. This clinical-stage biopharma could be a big ...